Avalyn Pharma Common Stock Long Term Debt

Avalyn Pharma Common Stock posts a long-term debt of $16M as of June 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Long-Term Debt is one piece of Avalyn Pharma Common Stock's financial statement story. At $16M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AVLN's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Avalyn Pharma Common Stock's other metric pages and overview cover the third.

Judging Avalyn Pharma Common Stock against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $16M here, then scan peer and history charts to see if the gap is persistent.